Inactive Instrument

CymaBay Therapeutics, Inc.

Equities

CBAY

US23257D1037

Biotechnology & Medical Research

CymaBay Therapeutics, Inc. Receives $5 Million Payment for Arhalofenate from Kowa Pharmaceuticals America

January 08, 2018 at 08:00 am

CymaBay Therapeutics, Inc. announced it has received a $5 million milestone payment from Kowa Pharmaceuticals America for the initiation of a study evaluating the pharmacokinetics (PK) of arhalofenate in subjects with renal impairment.

Latest news about CymaBay Therapeutics, Inc.

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	03-22	MT
CymaBay Therapeutics, Inc. Announces Board Changes	03-22	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	03-21	CI
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	03-21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	03-21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	03-21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	03-21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	03-14	CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	03-11	MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	03-04	MT
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	03-04	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26	02-20	MT
UBS Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts Price Target to $32.50 From $25	02-14	MT
LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform From Outperform	02-14	MT
Piper Sandler Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $33	02-14	MT
North American Morning Briefing :Stock Futures -2-	02-14	DJ
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	02-13	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy	02-13	MT
JonesTrading Downgrades CymaBay Therapeutics to Hold From Buy	02-13	MT
Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $30	02-13	MT
William Blair Downgrades CymaBay Therapeutics to Market Perform From Outperform	02-13	MT
BTIG Downgrades CymaBay Therapeutics to Neutral From Buy	02-13	MT
HC Wainwright Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts PT to $32.50 From $28	02-13	MT

Chart CymaBay Therapeutics, Inc.

Duration

Period

More charts

Company Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.49%	126B
REGENERON PHARMACEUTICALS, INC.	+23.95%	118B
ARGENX SE	+23.67%	27.87B
BIONTECH SE	-17.81%	20.95B
GENMAB A/S	-14.97%	16.92B
BEIGENE, LTD.	-14.60%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+9.29%	14.84B
WUXI APPTEC CO., LTD.	-46.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+52.95%	14.08B

Bio Therapeutic Drugs